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Introduction
Degenerative aortic valve disease is frequently found in elderly 
people. However, approximately 30% of elderly patients with se-
vere aortic stenosis (AS) remain unreferred and untreated because 
these patients are considered too high risk or inappropriate for 
conventional open heart surgery.1) Transcatheter aortic valve impl-
antation (TAVI) using a balloon expandable Sapien valve (Edwards 
Lifesciences, Irvine, CA, USA) or self-expandable CoreValve (Medtro-
nic, Minneapolis, MN, USA) has demonstrated favorable outcomes 
in patients with high surgical risk. The most common approach for 
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TAVI is the transfemoral approach because the relatively large pro-
file (18 Fr) of the delivery catheter requires an access route with a dia-
meter larger than 6 mm. However, peripheral arterial disease (PAD) 
is also relatively common in elderly patients with AS because degen-
erative aortic valve disease shares many characteristics with ath-
erosclerotic disease.2) When a transfemoral approach is not feasible 
due to small or diseased iliofemoral arteries, alternative access rou-
tes such as the transapical approach, transsubclavian approach, as 
well as direct aortic access via minimal thoracotomy may be consi-
dered.3)4)
In this case report, we present the first Korean patient with symp-
tomatic severe AS at high surgical risk accompanied by bilateral il-
iofemoral artery disease that was successfully treated with TAVI us-
ing a CoreValve by transsubclavian approach. 
Case
An 82-year-old male patient presented with worsening symptoms 
of chest discomfort and exertional dyspnea {New York Heart Asso-
ciation (NYHA) III} for 2 months. He had past medical history of hy-
pertension and dyslipidemia. Four years ago, the patient had been 
treated with percutaneous coronary intervention with implantation 
of stents at the left main artery and the distal left circumflex artery. 
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At that time he also underwent percutaneous transluminal angio-
plasty with implantation of self-expandable nitinol stents at the bi-
lateral iliac arteries. On admission, transthoracic and transesopha-
geal echocardiography showed severe AS and mild aortic regurgit-
ation (AR) due to degenerative change with calcification (Fig. 1). The 
aortic valve area was 0.44 cm2. The peak and mean pressure gradi-
ents across the aortic valve were estimated to be 97 and 59 mm Hg, 
respectively, while the diameter of the aortic annulus by echocar-
diography was 25 mm. The left ventricle (LV) showed a dilated end-
diastolic dimension (64 mm) with LV hypertrophy. The LV systolic 
function was globally reduced with an LV ejection fraction (EF) of 
39%. Based on the coronary angiography, the stent at the left main 
artery was patent. However, the stent implanted at the distal left 
circumflex artery showed in-stent restenosis, which was subse-
quently treated with a 3×30 mm paclitaxel-eluting balloon (SeQu-
ent® Please, B. Braun Melsungen AG, Berlin, Germany). The previ-
ously inserted stents at the right and left iliac arteries were patent, 
however computed tomography (CT) angiography revealed that the 
minimal lumen diameter of the stented right iliac artery was 5.5 mm 
and that of the left iliac artery was 4.5 mm. Both common femoral 
arteries also showed significant stenosis with a minimum lumen di-
ameter of 4.0 mm (Fig. 2). The diameter of the left subclavian artery 
was measured to be 7 mm on CT angiography. The calculated Eu-
roSCORE was 44.08%. 
In this patient we decided to perform TAVI by transsubclavian ap-
proach. The procedure was carried out in a hybrid operating room 
A   B  
Fig. 1. Transthoracic echocardiography showed severely narrowed aortic valve area (0.44 cm2) measured by the continuity equation (A), and color Doppler 
revealed aliasing due to severe aortic stenosis (B).
Fig. 2. Angiography and computed tomography image showed iliofemoral arteries with severe peripheral arterial occlusive disease. Previous stent at Lt. 
common iliac artery was patent but showed a minimum diameter of 4.5 mm and both common femoral arteries showed a minimum diameter of 4.0 mm. 
Lt. CIA: left common iliac artery, Rt. CFA: right common femoral artery, Lt. CFA: left common femoral artery.
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under general anesthesia. After surgical exposure of the left subcla-
vian artery, a 0.035 inch Amplatz Super Stiff wire (Boston Scientific, 
Natick, MA, USA) was inserted into the LV through an 18 Fr intro-
ducer sheath (Fig. 3). Balloon dilation of the stenotic aortic valve was 
performed with a 23 mm balloon (Z-med, NuMED Inc., Hopkinton, 
NY, USA) under rapid pacing using a temporary pacemaker. Under 
angiographic guidance, a 29 mm CoreValve was slowly deployed 
at the aortic annulus. An immediate post-procedural aortogram sh-
owed good position of the CoreValve with mild AR (Fig. 4). The vas-
cular access site at the left subclavian artery was closed surgically 
without any complications. The post-procedural echocardiography 
demonstrated well functioning bioprosthetic aortic valve with mild 
paravalvular AR. The peak and mean pressure gradients across the 
aortic valve decreased from 97 and 59 mm Hg to 42 and 23 mm Hg, 
respectively. The aortic valve area increased from 0.44 cm2 to 2.86 
cm2. The LVEF improved from 39% to 52%. Four days post proce-
dure, the patient was discharged with improved symptoms (NYHA I). 
There was no sign of stroke or any conduction abnormality as indi-
cated by the electrocardiogram. The patient has been free from any 
major cardiovascular events or symptom aggravation for a total 
follow-up duration of 6 months.
Discussion
Transcatheter aortic valve implantation has emerged as a promis-
ing alternative treatment modality to surgical aortic valve replace-
ment for patients with severe AS at high surgical risk. Patients with 
an estimated mortality risk >20% by logistic EuroSCORE or >10% by 
the Society of Thoracic Surgeons score system are generally con-
sidered candidates for the TAVI procedure. In addition, combined re-
spiratory failure, pulmonary hypertension, previous cardiac surgery, 
right ventricular failure, hostile thorax (such as radiation, burns, pre-
vious thoracic pleurodesis, or multiple thoracotomies), severe con-
nective tissue disease, liver cirrhosis, cachexia, and porcelain aorta 
are further indications for TAVI. Currently, two types of stented val-
ves, the balloon-expandable Edwards SAPIEN valve and the self-ex-
pandable CoreValve system are commonly used for the percutane-
ous treatment of severe AS. There has been no randomized study 
comparing the two systems to date. However, the procedural suc-
cess rates (>95%) have been reported to be high with both valves. 
The mortality rates are similar at 30 days (Edwards 12% vs. CoreV-
Fig. 3. CoreValve delivery system is advanced through 18 Fr sheath insert-
ed into the Lt. subclavian artery.
Fig. 4. CoreValve delivery catheter and bioprosthetic valve deployed across the aortic valve (A) and spontaneously expanded. An aortogram showed good 
positioning of the CoreValve with mild aortic regurgitation (B).
A   B  
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alve 11%, p=0.99) and one year (Edwards 18% vs. CoreValve 21%) for 
both systems. The need for pacemaker appears to be significantly 
higher with the CoreValve.5)
Commonly, the transfemoral route is used for the TAVI procedure 
due to the vessel diameter requirement of >6 mm for the 18 Fr device 
introducer sheath and delivery catheter. However, when transfemo-
ral approach is not amenable due to the concomitant PAD, alterna-
tive routes by transapical, transsubclavian or direct aortic access 
through thoracotomy can be utilized for the TAVI procedure. The pa-
tient we observed here is the first Korean case of TAVI by transsub-
clavian approach using a CoreValve. Recent studies have shown 
that the safety of transsubclavian TAVI is not inferior to transfem-
oral TAVI.6) Petronio et al.7) reported a 100% procedural success 
rate and 0% intraprocedural mortality according to the analysis of 
54 transsubclavian approach cases. Thirty-day mortality was 0% 
(vs. 6.1% in transfemoral approach group, p=0.13) and the six-month 
mortality rate was 9.4% (vs. 15.8%, p=0.44) showing no difference 
compared with transfemoral TAVI.
Moynagh et al.8) reported that the transsubclavian TAVI achieved 
better outcomes compared with the transfemoral approach in opti-
mal valve positioning (88.6% vs. 60.5%, p<0.0001) and in major ad-
verse cardiovascular and cerebrovascular events (2.9% vs. 13.4%, 
p=0.09), even though transsubclavian TAVI patients had significantly 
higher EuroSCOREs because they were frequently accompanied by 
PAD, coronary artery disease, prior myocardial infarct, and prior per-
cutaneous coronary intervention experience. CoreValve is currently 
not available for the transapical approach. However, patients treated 
by transapical approach using Edwards SAPIEN showed significantly 
lower one-year survival than those treated by transfemoral appro-
ach. More renal failure and stroke events were observed in the tr-
ansapical TAVI group compared with transfemoral TAVI group.5) Tr-
ansapical approach generally accompanies the risk from general 
anesthesia, thoracotomy and the incision of the LV apex. Moreover, 
patients with structural change of the LV due to remodeling and 
distorted angle, the risk of transapical TAVI may increase.9) By con-
trast, transsubclavian approach can be safely performed via local 
anesthesia combined with administration of a mild systemic seda-
tive and analgesic agent. Therefore, if the transfemoral approach is 
not applicable due combined PAD in a patient with severe AS requir-
ing TAVI procedure, and if the subclavian artery has a diameter >6 
mm, a transsubclavian approach should be considered as a primary 
alternative route.
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